1 | complicated | 4,759 |
2 | complicating | 387 |
3 | scalded | 40 |
4 | buttressed | 21 |
5 | tutored | 17 |
6 | six-coordinated | 11 |
7 | hyperplasia/lower | 9 |
8 | wrought | 9 |
9 | nitrite-positive | 8 |
10 | sun-damaged | 8 |
11 | deflected | 7 |
12 | desalting | 6 |
13 | mingled | 6 |
14 | documentated | 4 |
15 | eight-coordinated | 4 |
16 | nosocomial-acquired | 4 |
17 | non-catheter-related | 3 |
18 | non-pyelonephritic | 3 |
19 | nondilating | 3 |
20 | prostate-induced | 3 |
21 | 'confounding | 2 |
22 | 'inhalation | 2 |
23 | 83972-coated | 2 |
24 | bp-pcav | 2 |
25 | brr2 | 2 |
26 | choreographed | 2 |
27 | control-aptamer | 2 |
28 | gedvidisplayed | 2 |
29 | h252 | 2 |
30 | hrv-c. | 2 |
31 | hypercoagulability-related | 2 |
32 | ldl-uptake | 2 |
33 | lepidocrocite | 2 |
34 | mmp-1/mmp-3 | 2 |
35 | mrsa-confirmed | 2 |
36 | n-desmethylimatinib | 2 |
37 | n-nitroso-tris-chloroethylurea | 2 |
38 | piperidin-4-one | 2 |
39 | pre-circumcision | 2 |
40 | probable/possible | 2 |
41 | relapse/rehospitalisation | 2 |
42 | samd4 | 2 |
43 | trials.regarding | 2 |
44 | ultrafiltrate/dialysate | 2 |
45 | ureolysis | 2 |
46 | 0.68mol/mol | 1 |
47 | 1.29/1,000 | 1 |
48 | 125-iothalamate | 1 |
49 | 1981-85 | 1 |
50 | 2',3'-dideoxy-2'-fluoro-3'-c-hydroxymethyl-2',3'-endo-methylene-uridine | 1 |
51 | 2,3-cis-flavan-3-ols | 1 |
52 | 2,3-dibromoquinoxaline | 1 |
53 | 2,6-dichlorophenoloindophenol | 1 |
54 | 2-amino-4h-chromenes | 1 |
55 | 2-methyl-3,5-dibromothiophene | 1 |
56 | 23.9±16.6 | 1 |
57 | 28±10.7 | 1 |
58 | 3-epi-25-oh-d3 | 1 |
59 | 3.03.scalding | 1 |
60 | 33,269 | 1 |
61 | 3t3-fibroblasts | 1 |
62 | 4-chlorotryptophan | 1 |
63 | 5:4:1 | 1 |
64 | 6-cm2 | 1 |
65 | 69,475 | 1 |
66 | 730kda | 1 |
67 | 89-khz | 1 |
68 | 9-methylcarbazole | 1 |
69 | 93.2°-120.5° | 1 |
70 | adrenaline/collagen | 1 |
71 | ah-ni-htst | 1 |
72 | alcohol-affected | 1 |
73 | alme3 | 1 |
74 | anti-atherogenesis | 1 |
75 | arylacrylamides | 1 |
76 | arylpyruvates | 1 |
77 | asp-glu-val-asp-pna | 1 |
78 | atherothrombogenesis | 1 |
79 | bad/bax | 1 |
80 | bispirooxindoles | 1 |
81 | blind-read-analysis | 1 |
82 | bmd-l-spine | 1 |
83 | camno3 | 1 |
84 | camp–pka | 1 |
85 | cci-mice | 1 |
86 | chymiaphilosophica | 1 |
87 | decyanation/aromatization | 1 |
88 | devd-peptides | 1 |
89 | di-amniotic | 1 |
90 | dihydrotesterone | 1 |
91 | disdains | 1 |
92 | disulfide-bonds | 1 |
93 | dmmd | 1 |
94 | docetaxol | 1 |
95 | duckweeds | 1 |
96 | ebna2-activity | 1 |
97 | ec958-mediated | 1 |
98 | end-healing | 1 |
99 | epoxy-janthitrems | 1 |
100 | erk1/2/ | 1 |
101 | fe-substrate | 1 |
102 | gcf-samples | 1 |
103 | glabrata-associated | 1 |
104 | glu3 | 1 |
105 | glycosylsulfanyloxadiazoles | 1 |
106 | group:45 | 1 |
107 | gαi1/2/3 | 1 |
108 | hand-determined | 1 |
109 | hantzschia | 1 |
110 | harm-both | 1 |
111 | hchs | 1 |
112 | hmpv-rna | 1 |
113 | hslu2 | 1 |
114 | humus | 1 |
115 | hypercholesterolamias | 1 |
116 | hyperplasia-lower | 1 |
117 | i612 | 1 |
118 | immobilisations | 1 |
119 | immunoassay-positive | 1 |
120 | infections-including | 1 |
121 | lah-3gene | 1 |
122 | mbig | 1 |
123 | mek/erk-signaling | 1 |
124 | melamine-related | 1 |
125 | mesotheliosarcoma | 1 |
126 | mgh+ | 1 |
127 | minmisation | 1 |
128 | monitoring/counselling | 1 |
129 | monoanalgesia | 1 |
130 | mzf1 | 1 |
131 | nct01119963supported | 1 |
132 | ndm-4 | 1 |
133 | non-confirmation | 1 |
134 | non-immunoallergic | 1 |
135 | non-melancholics | 1 |
136 | normal/nondepressed | 1 |
137 | occured-64 | 1 |
138 | octocorals | 1 |
139 | offungal | 1 |
140 | parapegics | 1 |
141 | penumbra-visualized | 1 |
142 | phe104 | 1 |
143 | phospho-tyr-655 | 1 |
144 | pka/creb | 1 |
145 | plasmas/sera | 1 |
146 | postktx | 1 |
147 | price-fixing | 1 |
148 | pro445 | 1 |
149 | rage-en-rage | 1 |
150 | rates.a | 1 |
151 | rates.trial | 1 |
152 | redox-homeostasis | 1 |
153 | ridiculed | 1 |
154 | s-lercanidipine | 1 |
155 | salpingostomatolysis | 1 |
156 | self-applications | 1 |
157 | ser210 | 1 |
158 | ser218 | 1 |
159 | serum-triglycerides | 1 |
160 | sex-unprotected | 1 |
161 | skalded | 1 |
162 | slercanidipine | 1 |
163 | small-but-important-difference | 1 |
164 | soiled.perineal | 1 |
165 | sonocytology | 1 |
166 | soxr | 1 |
167 | spiroindanes | 1 |
168 | supercontinents | 1 |
169 | swi6 | 1 |
170 | tgf-signaling | 1 |
171 | thiazoloquinazolines | 1 |
172 | tyrannosauridae | 1 |
173 | water-loss-minimization | 1 |
174 | well-acceptance | 1 |
175 | year-of-reporting | 1 |
176 | yokukasan | 1 |
177 | zn7-mt1 | 1 |
178 | ⩾1-log10 | 1 |
1 | 'confounding | 2 |
2 | 'inhalation | 2 |
3 | 0.68mol/mol | 1 |
4 | 1.29/1,000 | 1 |
5 | 125-iothalamate | 1 |
6 | 1981-85 | 1 |
7 | 2',3'-dideoxy-2'-fluoro-3'-c-hydroxymethyl-2',3'-endo-methylene-uridine | 1 |
8 | 2,3-cis-flavan-3-ols | 1 |
9 | 2,3-dibromoquinoxaline | 1 |
10 | 2,6-dichlorophenoloindophenol | 1 |
11 | 2-amino-4h-chromenes | 1 |
12 | 2-methyl-3,5-dibromothiophene | 1 |
13 | 23.9±16.6 | 1 |
14 | 28±10.7 | 1 |
15 | 3-epi-25-oh-d3 | 1 |
16 | 3.03.scalding | 1 |
17 | 33,269 | 1 |
18 | 3t3-fibroblasts | 1 |
19 | 4-chlorotryptophan | 1 |
20 | 5:4:1 | 1 |
21 | 6-cm2 | 1 |
22 | 69,475 | 1 |
23 | 730kda | 1 |
24 | 83972-coated | 2 |
25 | 89-khz | 1 |
26 | 9-methylcarbazole | 1 |
27 | 93.2°-120.5° | 1 |
28 | adrenaline/collagen | 1 |
29 | ah-ni-htst | 1 |
30 | alcohol-affected | 1 |
31 | alme3 | 1 |
32 | anti-atherogenesis | 1 |
33 | arylacrylamides | 1 |
34 | arylpyruvates | 1 |
35 | asp-glu-val-asp-pna | 1 |
36 | atherothrombogenesis | 1 |
37 | bad/bax | 1 |
38 | bispirooxindoles | 1 |
39 | blind-read-analysis | 1 |
40 | bmd-l-spine | 1 |
41 | bp-pcav | 2 |
42 | brr2 | 2 |
43 | buttressed | 21 |
44 | camno3 | 1 |
45 | camp–pka | 1 |
46 | cci-mice | 1 |
47 | choreographed | 2 |
48 | chymiaphilosophica | 1 |
49 | complicated | 4,759 |
50 | complicating | 387 |
51 | control-aptamer | 2 |
52 | decyanation/aromatization | 1 |
53 | deflected | 7 |
54 | desalting | 6 |
55 | devd-peptides | 1 |
56 | di-amniotic | 1 |
57 | dihydrotesterone | 1 |
58 | disdains | 1 |
59 | disulfide-bonds | 1 |
60 | dmmd | 1 |
61 | docetaxol | 1 |
62 | documentated | 4 |
63 | duckweeds | 1 |
64 | ebna2-activity | 1 |
65 | ec958-mediated | 1 |
66 | eight-coordinated | 4 |
67 | end-healing | 1 |
68 | epoxy-janthitrems | 1 |
69 | erk1/2/ | 1 |
70 | fe-substrate | 1 |
71 | gcf-samples | 1 |
72 | gedvidisplayed | 2 |
73 | glabrata-associated | 1 |
74 | glu3 | 1 |
75 | glycosylsulfanyloxadiazoles | 1 |
76 | group:45 | 1 |
77 | gαi1/2/3 | 1 |
78 | h252 | 2 |
79 | hand-determined | 1 |
80 | hantzschia | 1 |
81 | harm-both | 1 |
82 | hchs | 1 |
83 | hmpv-rna | 1 |
84 | hrv-c. | 2 |
85 | hslu2 | 1 |
86 | humus | 1 |
87 | hypercholesterolamias | 1 |
88 | hypercoagulability-related | 2 |
89 | hyperplasia-lower | 1 |
90 | hyperplasia/lower | 9 |
91 | i612 | 1 |
92 | immobilisations | 1 |
93 | immunoassay-positive | 1 |
94 | infections-including | 1 |
95 | lah-3gene | 1 |
96 | ldl-uptake | 2 |
97 | lepidocrocite | 2 |
98 | mbig | 1 |
99 | mek/erk-signaling | 1 |
100 | melamine-related | 1 |
101 | mesotheliosarcoma | 1 |
102 | mgh+ | 1 |
103 | mingled | 6 |
104 | minmisation | 1 |
105 | mmp-1/mmp-3 | 2 |
106 | monitoring/counselling | 1 |
107 | monoanalgesia | 1 |
108 | mrsa-confirmed | 2 |
109 | mzf1 | 1 |
110 | n-desmethylimatinib | 2 |
111 | n-nitroso-tris-chloroethylurea | 2 |
112 | nct01119963supported | 1 |
113 | ndm-4 | 1 |
114 | nitrite-positive | 8 |
115 | non-catheter-related | 3 |
116 | non-confirmation | 1 |
117 | non-immunoallergic | 1 |
118 | non-melancholics | 1 |
119 | non-pyelonephritic | 3 |
120 | nondilating | 3 |
121 | normal/nondepressed | 1 |
122 | nosocomial-acquired | 4 |
123 | occured-64 | 1 |
124 | octocorals | 1 |
125 | offungal | 1 |
126 | parapegics | 1 |
127 | penumbra-visualized | 1 |
128 | phe104 | 1 |
129 | phospho-tyr-655 | 1 |
130 | piperidin-4-one | 2 |
131 | pka/creb | 1 |
132 | plasmas/sera | 1 |
133 | postktx | 1 |
134 | pre-circumcision | 2 |
135 | price-fixing | 1 |
136 | pro445 | 1 |
137 | probable/possible | 2 |
138 | prostate-induced | 3 |
139 | rage-en-rage | 1 |
140 | rates.a | 1 |
141 | rates.trial | 1 |
142 | redox-homeostasis | 1 |
143 | relapse/rehospitalisation | 2 |
144 | ridiculed | 1 |
145 | s-lercanidipine | 1 |
146 | salpingostomatolysis | 1 |
147 | samd4 | 2 |
148 | scalded | 40 |
149 | self-applications | 1 |
150 | ser210 | 1 |
151 | ser218 | 1 |
152 | serum-triglycerides | 1 |
153 | sex-unprotected | 1 |
154 | six-coordinated | 11 |
155 | skalded | 1 |
156 | slercanidipine | 1 |
157 | small-but-important-difference | 1 |
158 | soiled.perineal | 1 |
159 | sonocytology | 1 |
160 | soxr | 1 |
161 | spiroindanes | 1 |
162 | sun-damaged | 8 |
163 | supercontinents | 1 |
164 | swi6 | 1 |
165 | tgf-signaling | 1 |
166 | thiazoloquinazolines | 1 |
167 | trials.regarding | 2 |
168 | tutored | 17 |
169 | tyrannosauridae | 1 |
170 | ultrafiltrate/dialysate | 2 |
171 | ureolysis | 2 |
172 | water-loss-minimization | 1 |
173 | well-acceptance | 1 |
174 | wrought | 9 |
175 | year-of-reporting | 1 |
176 | yokukasan | 1 |
177 | zn7-mt1 | 1 |
178 | ⩾1-log10 | 1 |
1 | mgh+ | 1 |
2 | hrv-c. | 2 |
3 | erk1/2/ | 1 |
4 | 1.29/1,000 | 1 |
5 | ser210 | 1 |
6 | ⩾1-log10 | 1 |
7 | 5:4:1 | 1 |
8 | mzf1 | 1 |
9 | zn7-mt1 | 1 |
10 | i612 | 1 |
11 | h252 | 2 |
12 | 6-cm2 | 1 |
13 | brr2 | 2 |
14 | hslu2 | 1 |
15 | mmp-1/mmp-3 | 2 |
16 | gαi1/2/3 | 1 |
17 | 3-epi-25-oh-d3 | 1 |
18 | alme3 | 1 |
19 | camno3 | 1 |
20 | glu3 | 1 |
21 | ndm-4 | 1 |
22 | phe104 | 1 |
23 | occured-64 | 1 |
24 | samd4 | 2 |
25 | pro445 | 1 |
26 | group:45 | 1 |
27 | phospho-tyr-655 | 1 |
28 | 69,475 | 1 |
29 | 1981-85 | 1 |
30 | 23.9±16.6 | 1 |
31 | swi6 | 1 |
32 | 28±10.7 | 1 |
33 | ser218 | 1 |
34 | 33,269 | 1 |
35 | rates.a | 1 |
36 | chymiaphilosophica | 1 |
37 | 730kda | 1 |
38 | n-nitroso-tris-chloroethylurea | 2 |
39 | hantzschia | 1 |
40 | monoanalgesia | 1 |
41 | camp–pka | 1 |
42 | mesotheliosarcoma | 1 |
43 | asp-glu-val-asp-pna | 1 |
44 | hmpv-rna | 1 |
45 | plasmas/sera | 1 |
46 | pka/creb | 1 |
47 | n-desmethylimatinib | 2 |
48 | non-immunoallergic | 1 |
49 | non-pyelonephritic | 3 |
50 | di-amniotic | 1 |
51 | prostate-induced | 3 |
52 | scalded | 40 |
53 | skalded | 1 |
54 | sun-damaged | 8 |
55 | choreographed | 2 |
56 | mingled | 6 |
57 | ridiculed | 1 |
58 | mrsa-confirmed | 2 |
59 | hand-determined | 1 |
60 | nosocomial-acquired | 4 |
61 | tutored | 17 |
62 | normal/nondepressed | 1 |
63 | buttressed | 21 |
64 | complicated | 4,759 |
65 | glabrata-associated | 1 |
66 | ec958-mediated | 1 |
67 | melamine-related | 1 |
68 | non-catheter-related | 3 |
69 | hypercoagulability-related | 2 |
70 | eight-coordinated | 4 |
71 | six-coordinated | 11 |
72 | 83972-coated | 2 |
73 | documentated | 4 |
74 | alcohol-affected | 1 |
75 | deflected | 7 |
76 | sex-unprotected | 1 |
77 | nct01119963supported | 1 |
78 | gedvidisplayed | 2 |
79 | penumbra-visualized | 1 |
80 | dmmd | 1 |
81 | tyrannosauridae | 1 |
82 | cci-mice | 1 |
83 | well-acceptance | 1 |
84 | small-but-important-difference | 1 |
85 | rage-en-rage | 1 |
86 | ldl-uptake | 2 |
87 | probable/possible | 2 |
88 | 9-methylcarbazole | 1 |
89 | lah-3gene | 1 |
90 | 2-methyl-3,5-dibromothiophene | 1 |
91 | 2',3'-dideoxy-2'-fluoro-3'-c-hydroxymethyl-2',3'-endo-methylene-uridine | 1 |
92 | 2,3-dibromoquinoxaline | 1 |
93 | s-lercanidipine | 1 |
94 | slercanidipine | 1 |
95 | bmd-l-spine | 1 |
96 | piperidin-4-one | 2 |
97 | dihydrotesterone | 1 |
98 | 125-iothalamate | 1 |
99 | fe-substrate | 1 |
100 | ultrafiltrate/dialysate | 2 |
101 | lepidocrocite | 2 |
102 | nitrite-positive | 8 |
103 | immunoassay-positive | 1 |
104 | mbig | 1 |
105 | 3.03.scalding | 1 |
106 | 'confounding | 2 |
107 | trials.regarding | 2 |
108 | infections-including | 1 |
109 | end-healing | 1 |
110 | tgf-signaling | 1 |
111 | mek/erk-signaling | 1 |
112 | monitoring/counselling | 1 |
113 | complicating | 387 |
114 | nondilating | 3 |
115 | desalting | 6 |
116 | year-of-reporting | 1 |
117 | price-fixing | 1 |
118 | harm-both | 1 |
119 | soiled.perineal | 1 |
120 | offungal | 1 |
121 | rates.trial | 1 |
122 | 0.68mol/mol | 1 |
123 | 2,6-dichlorophenoloindophenol | 1 |
124 | docetaxol | 1 |
125 | 4-chlorotryptophan | 1 |
126 | yokukasan | 1 |
127 | adrenaline/collagen | 1 |
128 | pre-circumcision | 2 |
129 | 'inhalation | 2 |
130 | non-confirmation | 1 |
131 | relapse/rehospitalisation | 2 |
132 | minmisation | 1 |
133 | water-loss-minimization | 1 |
134 | decyanation/aromatization | 1 |
135 | control-aptamer | 2 |
136 | hyperplasia-lower | 1 |
137 | hyperplasia/lower | 9 |
138 | soxr | 1 |
139 | hypercholesterolamias | 1 |
140 | parapegics | 1 |
141 | non-melancholics | 1 |
142 | duckweeds | 1 |
143 | disulfide-bonds | 1 |
144 | arylacrylamides | 1 |
145 | serum-triglycerides | 1 |
146 | devd-peptides | 1 |
147 | bispirooxindoles | 1 |
148 | glycosylsulfanyloxadiazoles | 1 |
149 | gcf-samples | 1 |
150 | spiroindanes | 1 |
151 | 2-amino-4h-chromenes | 1 |
152 | thiazoloquinazolines | 1 |
153 | arylpyruvates | 1 |
154 | hchs | 1 |
155 | redox-homeostasis | 1 |
156 | atherothrombogenesis | 1 |
157 | anti-atherogenesis | 1 |
158 | blind-read-analysis | 1 |
159 | ureolysis | 2 |
160 | salpingostomatolysis | 1 |
161 | octocorals | 1 |
162 | 2,3-cis-flavan-3-ols | 1 |
163 | epoxy-janthitrems | 1 |
164 | disdains | 1 |
165 | self-applications | 1 |
166 | immobilisations | 1 |
167 | supercontinents | 1 |
168 | 3t3-fibroblasts | 1 |
169 | humus | 1 |
170 | wrought | 9 |
171 | ah-ni-htst | 1 |
172 | bp-pcav | 2 |
173 | bad/bax | 1 |
174 | postktx | 1 |
175 | sonocytology | 1 |
176 | ebna2-activity | 1 |
177 | 89-khz | 1 |
178 | 93.2°-120.5° | 1 |